Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: A biochemical signature of an enhanced in vivo low-density lipoprotein oxidation

Journal of Hypertension

Volumn 13, Issue 1, 1995, Pages 129-138

  Maggi, Elena ^a   Marchesi, Eugenia ^a   Ravetta, Valentina ^a   Martignoni, Alessandra ^a   Finardi, Giorgio ^a   Bellomo, Giorgio ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Atherosclerosis; Autoantibody; Hypertension; Low density lipoprotein; Oxidation

Indexed keywords

ANTIOXIDANT; AUTOANTIBODY; COPPER ION; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ADULT; AGE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LIPID OXIDATION; MALE; PRIORITY JOURNAL; PROTEIN MODIFICATION;

EID: 0028967190     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Jameson M, Dai FX, Lusher T, Skopec J, Diederich A, Diederich D: Endothelium-derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 1993, 21:280-288.
2. Kumar KW, Das UM: Are free radicals involved in the patho-biology of human essential hypertension? Free Radic Res Com- mun 1993, 19:59-66.
3. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456.
4. Wei EP, Kontos HA, Christman CW, DeWitt DS, Povlischock JT: Superoxide generation and reversal of acetylcholine-induced cerebral arteriolar dilation after acute hypertension. Circ Res 1985, 57:781-787.
5. De Bruyn VH, Nuno DW, Cappelli-Bigazzi M, Dole WP, Lamping KG: Effect of acute hypertension in the coronary circulation: role of mechanical factors and oxygen radicals. J Hyper- tens 1994, 12:163-172.
6. Hunter GC, Dubick MA, Keen CL, Eskelson CD: Effects of hypertension on aortic antioxidant status in human abdominal aneurysmal and occlusive disease. Proc Soc Exp Biol Med 1991, 196:273-279.
7. Gutteridge JMC, Halliwell B: The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1990, 15:129-135.
8. Frankel EN, Neff WE: Formation of malondialdehyde from lipid oxidation products. Biochim Biophys Acta 1983, 754:264-270.
9. Esterbauer H, Benedetti A, Lang J, Fulceri R, Fauler G, Com-porti M: Studies on the formation of 4-OH-nonenal during microsomal lipid peroxidation. Biochim Biophys Acta 1986, 876:154-166.
10. Maggi E, Marchesi E, Ravetta V, Falaschi F, Finardi G, Bellomo G: Low-density lipoprotein oxidation in essential hypertension. J Hypertens 1993, 11:1103-1111.
11. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidyl- choline: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988, 85:2805-2809.
12. Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA: Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980, 77:2214-2218.
13. Morel DW, Hessler JR, Chisolm GM: Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983, 24:1070-1076.
14. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, et al.: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989, 86:1372-1376.
15. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
16. Lavy A, Brook GJ, Danker G, Amotz AB, Aviram M: Enhanced in vitro oxidation of plasma lipoproteins derived from hyper- cholesterolemic patients. Metabolism 1991, 40:794-799.
17. Rengstrom J, Nilsson J, Tornvall P, Landou C, Hampsten A: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992, 339:1183-1186.
18. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, et al.: Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994, 45:876-883.
19. Carew TE, Schwenke DC, Steinberg D: An atherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA 1987, 84:7725-7729.
20. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993, 328:1450-1456.
21. Esterbauer H, Gebicki J, Puhl H, Jurgens G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992, 13:341-390.
22. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al.: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
23. Bellaro G, Barsotti A, Nicolaides AN,: ‘Ultrasonic Biopsy’, a non-invasive technique to evaluate the cardiovascular system and to follow-up the progression and regression of arteriosclerosis. Vasa 1991, 20:40-50.
24. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989, 6:67-75.
25. Jurgens G, Hoff HF, Chisolm GM 3rd, Esterbauer H: Modification of human serum low density lipoprotein by oxidation—characterization and pathophysiological implications. Chem Phys Lipids 1987, 45:315-336.
26. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL: Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 1994, 343:645-646.
27. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G: Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. Kidney Int 1994, 46:869-876.
28. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, et al.: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990, 10:325-335.
29. Jurgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP: Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein (a). Arterioscler Thromb 1993, 13:1689-1699.
30. Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Maggi E, et al.: In search of biological markers of high risk carotid artery atherosclerotic plaque: enhanced LDL oxidation. Eur J Vase Surg (in press).
31. White CR, Brock TA, Chang L, Crapo J, Briscoe P, Ku D, et al.: Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994, 91:1044-1048.
32. Morel DW, DiCorleto PE, Chisolm GM: Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984, 4:357-364.
33. Heinecke JW, Rosen H, Chait A: Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984, 74:1890-1894.
34. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990, 344:160-162.
35. Simon BC, Cunningham LD, Cohen RA: Oxidized low density 47. lipoproteins cause contraction and inhibit endothelium-depen-dent relaxation in the pig coronary artery. j Clin Invest 1990, 86:75-79.
36. Galle J, Bassenge E, Busse R: Oxidized low density lipopro- 48. teins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res 1990, 66:1287-1293.
37. Weisser B, Locher R, Mengden T, Sachinidis A, Vetter W: Oxi-49. dation of low-density lipoprotein increases vasoconstriction in vitro. J Hypertens 1991, 9 (suppl 6):S172-SI73.
38. Lusher TF, Vanhoutte PM, Boulanger C, DOHI C, Buhler FR,: Endothelial disfunction in hypertension. In Cardiovascular Sig- 50. nificance of Endothelium-Derived Vasoactive Factors. Edited by Rubanyi G. New York: Futura; 1991:199-221.
39. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with es- 51. sential hypertension. N Engl J Med 1990, 323:22-27.
40. Linder L, Kiowski W, Buhler FR, Luscher TF: Indirect evidence for release of endothelium-derived relaxing factor in 52. human forearm circulation in vivo. Blunted response to essential hypertension. Circulation 1990, 81:1762-1767.
41. Calver A, Collier J, Vallance P: The effects of local intraarterial 53. /V/G-monomethyl-L-arginine in hypertensive patients: the nitric oxide dilator mechanism appears impaired [abstract]. Clin Sci Colch 1991, 81:7P-8P. 54.
42. Stewart-Lee AL, Forster LA, Nourooz-Zadeh J, Ferns GAA, Anggard EE: Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler Thromb 1994, 14:494-499. 55.
43. Keaney JF, Graziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, et al.: Low-dose a-tochopherol improves and high dose a-tochophero! worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994, 93:844-851. 56.
44. Lusis AJ, Navab M: Lipoprotein oxidation and gene expression in the artery wall. New opportunities for pharmacological intervention in atherosclerosis. Biochem Pharmacol 1993, 46:2119-2126. 57.
45. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
46. Zhu W, Roma P, Pellegatta F, Catapano AL: Oxidized-LDL induce the expression of heat shock protein 70 in hu- 58. man endothelial cells. Biochem Biophys Res Commun 1994, 200:389-394.
47. Hashimoto T, Mosser RD, Tremblay J, Harriet P: Increased accumulation of hsp70 messenger RNA due to enhanced activation of heat shock transcription factor in spontaneously hypertensive rats. J Hypertens 1991, 9 (suppl 6):S170-S171.
48. Xu Q, Luef G, Weimann S, Gupta RS, Wolf H, Wick G: Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein-reactive antisera. Arterioscler Thromb 1993, 13:1763-1769.
49. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al.: Association of serum antibodies to heat- shock protein 65 with carotid atherosclerosis. Lancet 1993, 341:255-259.
50. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, et al.: Induction of arteriosclerosis in normocholesterolemic rabbits by immunisation with heat shock protein 65. Arterioscler Thromb 1992, 12:789-799.
51. McGill HC, Arias-Stella J, Carbonell LM: General findings of the International Atherosclerosis Project. Lab Invest 1968, 18:498-502.
52. Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP: Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981, 245:1225-1229.
53. Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991, 64:5-15.
54. Tertov W, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN: Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol 1990, 52:300-308.
55. Chazov El, Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IY,: Atherogenicity of blood plasma from patients with coronary atherosclerosis and its correction. Atheroscler Rev 1988, 17:9-20.
56. Croft KD, Dimmitt SB, Moulton C, Beilin LJ: Low density lipoprotein composition and oxidizability in coronary disease—apparent favourable effect of beta blockers. Atherosclerosis 1992, 97:123-130.
57. Godfrey EG, Stewart J, Dargie HJ, Reid JL, Dominiczak M, Hamilton CA, et al.: Effects of ACE inhibitors on oxidation of human low density lipoprotein. Br J Clin Pharmacol 1994, 37:63-66.
58. Henry DP: Antiperoxidative action of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 1991, 18 (suppl 1) :S6-SI0.